|
Video: What is a Stock Split?
|
|
Edesa Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing clinical-stage drugs for inflammatory and immune-related diseases. Co.'s primary product candidates include: EB05, which is a monoclonal antibody therapy for the treatment for Acute Respiratory Distress Syndrome in COVID-19 patients; and EB01, which is a secretory phospholipase 2 (sPLA2) inhibitor for the topical treatment for chronic allergic contact dermatitis, a potentially debilitating condition and occupational illness. Co.'s EB02 drug candidate represents a potential extension of its sPLA2 anti-inflammatory technology. Co.'s product candidate EB06, is a monoclonal antibody candidate. According to our Edesa Biotech stock split history records, Edesa Biotech has had 1 split. | |
|
Edesa Biotech (EDSA) has 1 split in our Edesa Biotech stock split history database. The split for EDSA took place on October 11, 2023. This was a 1 for 7 reverse split, meaning for each 7 shares of EDSA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split.
When a company such as Edesa Biotech conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the Edesa Biotech stock split history from start to finish, an original position size of 1000 shares would have turned into 142.857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Edesa Biotech shares, starting with a $10,000 purchase of EDSA, presented on a split-history-adjusted basis factoring in the complete Edesa Biotech stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/09/2014 |
|
End date: |
05/07/2024 |
|
Start price/share: |
$7.00 |
|
End price/share: |
$4.52 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-35.43% |
|
Average Annual Total Return: |
-4.28% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$6,456.17 |
|
Years: |
10.00 |
|
|
|
Date |
Ratio |
10/11/2023 | 1 for 7 |
|
|